Skip to content
Open access

Antimicrobial resistance trends and lineage distribution among invasive pneumococcal disease isolates pre- and post-pneumococcal conjugate vaccine introduction, South Africa.

Oct 2026 · Journal of Infection · Vol 93, pp. 106878 · 0 citations · 50 references
Medicine

TL;DR

PCVs substantially reduced AMR IPD in South Africa, but persistent PCV13 serotypes and expanding resistant non-vaccine-type lineages highlight the potential benefit of higher-valency PCVs, including PCV20.

Abstract

Objectives

Pneumococcal conjugate vaccines (PCV) have reduced antimicrobial-resistant invasive pneumococcal disease (IPD) globally. We evaluated trends in antimicrobial-resistant IPD and pneumococcal lineages before and after PCV13 introduction in South Africa.

Methods

We analysed national, laboratory-based IPD surveillance reported cases (2005-2020) and compared the incidence of resistant-IPD pre- and post-PCV introduction. Antimicrobial susceptibility testing was performed for six antibiotics, and penicillin-multidrug resistance (penicillin-MDR) was defined as penicillin nonsusceptibility plus resistance to ≥2 additional antibiotic classes. Whole-genome sequencing was used to determine serotypes, sequence types, global pneumococcal sequence clusters (GPSC), and antimicrobial resistance (AMR) determinants.

Results

Following PCV introduction, overall IPD and AMR IPD incidence declined substantially. Penicillin-cotrimoxazole nonsusceptible and penicillin-MDR IPD incidence decreased from 5.6 to 0.8 per 100,000 population (percentage decrease -86.5%, confidence intervals [CI] -90.5% to -81.4%) and 5.5 to 0.4 (-93.0%, -95.7% to -89.1%), respectively, in children <5 years, with smaller but significant reductions in the ≥5 years old. Despite these declines, residual PCV13 serotypes, particularly 19A and 19F, continued to contribute notably to penicillin-cotrimoxazole nonsusceptible and penicillin-MDR IPD, respectively, after PCV13 introduction. Non-vaccine serotypes (10A, 15A, 15B/C, 16F, 23B, and 35B) increasingly contributed to resistant IPD in the post-PCV13 era through the expansion of both vaccine-type and non-vaccine-type GPSC lineages.

Conclusion

PCVs substantially reduced AMR IPD in South Africa, but persistent PCV13 serotypes and expanding resistant non-vaccine-type lineages highlight the potential benefit of higher-valency PCVs, including PCV20.

Read PDF

Similar papers

Open access Oct 2026

Preparing for Next-Generation Vaccines: Breakthrough Invasive Pneumococcal Disease Patterns Post-PCV13 and Post-PPSV23 in Australia.

Serotype 3, included in all current conjugate formulations, dominated breakthrough for both vaccines, and in descriptive comparisons limited by small subgroup sizes, neither additional doses nor sequential vaccination was associated with lower vaccine-type proportions.

Shayan Sharifi, S. Pelton, Inci Yildirim et al. · 0 citations
Open access Oct 2026

Shifts in invasive pneumococcal disease epidemiology following the SARS-CoV-2 pandemic in Madrid, Spain: insights from a six-year hospital-based study

Invasive pneumococcal disease (IPD) incidence declined sharply during the COVID-19 pandemic and increased again thereafter, coinciding with substantial changes in respiratory virus circulation.

Patricia Brañas, J. C. Sanz Moreno, M. Castaño-Amores et al. · 0 citations
Review Open access Nov 2026

Mapping the pneumococcal disease landscape in India: a meta-analysis of literature from 2007 to 2024 on serotype prevalence and antimicrobial resistance patterns

Pneumococcal disease remains a major public health concern in India, with significant prevalence in both children and adults. Pneumococcal conjugate vaccine (PCV) 13 provides high serotype coverage in children and in adults; however, non-vaccine serotypes are emerging. Rising antimicrobial resistance and limited...

S. Taur, M. Keny, N. Kulkarni · 0 citations
Open access Oct 2026

Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease in Canada: A Canadian Immunization Research Network (CIRN) study

Abstract The effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) to prevent vaccine-serotype (VT) invasive pneumococcal disease (IPD) in children aged 2–59 months was assessed using data from 4 geographically defined areas in Canada with IPD surveillance, including immunization status. VT IPD cases an...

G. Deceuninck, N. Brousseau, Allison McGeer et al. · 0 citations
Open access Sep 2026

Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016–2021: a prospective cohort study

Streptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP) and a major source of morbidity and mortality in adults. Pneumococcal conjugate vaccines (PCVs) have substantially reduced invasive pneumococcal disease, but serotype replacement has led to shifts in pneumococcal CAP epid...

Samuel Etienne, W. Albrich, M. Pletz et al. · 0 citations
Open access Sep 2026

Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period

Streptococcus pneumoniae remains a leading cause of invasive disease in children, and nasopharyngeal carriage surveillance is essential for monitoring vaccine-driven changes in serotype distribution. However, carriage data from the Baltic states are scarce. We conducted a cross-sectional study to assess pneumococcal ca...

Hedija Cupeca, I. Zeltiņa, A. Villeruša et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.